cardiovascular agents

Summary

Summary: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Top Publications

  1. ncbi Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II
    C Riccioni
    Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
    Int Angiol 27:253-9. 2008
  2. ncbi Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
  3. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by r
    Ian Graham
    Department of Cardiology, Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  4. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
  5. ncbi Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in
    Martin B Leon
    Columbia University Medical Center, New York, New York 10032, USA
    JACC Cardiovasc Interv 3:1043-50. 2010
  6. ncbi Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    Michael Bohm
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin III, Homburg Saar, Germany
    Lancet 376:886-94. 2010
  7. ncbi Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  8. pmc Cardiovascular agents affect the tone of pulmonary arteries and veins in precision-cut lung slices
    Annette D Rieg
    Department of Anaesthesiology, Institute of Pharmacology and Toxicology, Medical Faculty Aachen, RWTH Aachen, Aachen, Germany
    PLoS ONE 6:e29698. 2011
  9. ncbi EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
    Kornelia Kotseva
    Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Cardiovasc Prev Rehabil 16:121-37. 2009
  10. ncbi Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event
    Jean Dallongevillle
    Department of Epidemiology and Public Health, INSERM U744, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    Heart 96:1744-9. 2010

Detail Information

Publications346 found, 100 shown here

  1. ncbi Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II
    C Riccioni
    Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
    Int Angiol 27:253-9. 2008
    ..PLC is involved in cellular metabolism and is transformed into two active substances, free L-carnitine and propionyl-coenzyme A in the mitochondria, which take part in fatty acid transfer and in the citric acid cycle, respectively...
  2. ncbi Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
    ..Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in heart failure...
  3. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by r
    Ian Graham
    Department of Cardiology, Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  4. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
    ..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
  5. ncbi Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in
    Martin B Leon
    Columbia University Medical Center, New York, New York 10032, USA
    JACC Cardiovasc Interv 3:1043-50. 2010
    ..The increased frequency of very late (>1 year) stent thrombosis (VLST) has raised concerns with regard to the safety of sirolimus-eluting stents and paclitaxel-eluting stents (PES)...
  6. ncbi Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    Michael Bohm
    Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin III, Homburg Saar, Germany
    Lancet 376:886-94. 2010
    ..We aimed to test our hypothesis by investigating the association between heart rate and events in this patient population...
  7. ncbi Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  8. pmc Cardiovascular agents affect the tone of pulmonary arteries and veins in precision-cut lung slices
    Annette D Rieg
    Department of Anaesthesiology, Institute of Pharmacology and Toxicology, Medical Faculty Aachen, RWTH Aachen, Aachen, Germany
    PLoS ONE 6:e29698. 2011
    b>Cardiovascular agents are pivotal in the therapy of heart failure. Apart from their action on ventricular contractility and systemic afterload, they affect pulmonary arteries and veins...
  9. ncbi EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
    Kornelia Kotseva
    Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Cardiovasc Prev Rehabil 16:121-37. 2009
    ....
  10. ncbi Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event
    Jean Dallongevillle
    Department of Epidemiology and Public Health, INSERM U744, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    Heart 96:1744-9. 2010
    ..To compare gender-related lifestyle changes and risk factor management after hospitalisation for a coronary event or revascularisation intervention in Europe...
  11. ncbi The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases
    Hua Cai
    Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Trends Pharmacol Sci 24:471-8. 2003
    ..Recently, efforts have been devoted to developing inhibitors of NAD(P)H oxidases that will provide useful experimental tools and might have therapeutic potential in the treatment of human diseases...
  12. ncbi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
    ..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
  13. ncbi Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice
    Giuseppe Danilo Norata
    Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
    Atherosclerosis 191:265-71. 2007
    ..In conclusion, P183/1 supplementation significantly decreases atherosclerosis in ApoE KO mice by affecting inflammatory cells recruitment and expression of pro-inflammatory chemokines in the vascular wall...
  14. pmc Predictors of medication adherence using a multidimensional adherence model in patients with heart failure
    Jia Rong Wu
    College of Nursing, University of Kentucky, Lexington, KY 40536 0232, USA
    J Card Fail 14:603-14. 2008
    ..The purpose of this study was to explore factors contributing to medication adherence in patients with HF by using the World Health Organization's multidimensional adherence model...
  15. ncbi Adherence in heart failure in the elderly: problem and possible solutions
    Martje H L van der Wal
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    Int J Cardiol 125:203-8. 2008
    ..Non-adherence to this regimen is a problem in many heart failure patients, leading to worsening symptoms, rehospitalization and decreased quality of life...
  16. pmc Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
    Jean Claude Tardif
    Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada
    Eur Heart J 30:540-8. 2009
    ..To evaluate the anti-anginal and anti-ischaemic efficacy of the selective I(f) current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy...
  17. pmc Use of herbal products and potential interactions in patients with cardiovascular diseases
    Ara Tachjian
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    J Am Coll Cardiol 55:515-25. 2010
    ..We also discuss health-related issues of herbal products and suggest ways to improve their safety to better protect the public from untoward effects...
  18. pmc NO/redox disequilibrium in the failing heart and cardiovascular system
    Joshua M Hare
    Johns Hopkins University School of Medicine, Department of Medicine, Cardiology Division, Baltimore, Maryland 21205, USA
    J Clin Invest 115:509-17. 2005
    ....
  19. ncbi Targeting the renin-angiotensin-aldosterone system in heart failure
    Chim C Lang
    Division of Cardiovascular and Diabetes Medicine, Mailbox 2, Ninewells Hospital and Medical School, Medical Research Institute, University of Dundee, Dundee DD1 9SY, UK
    Nat Rev Cardiol 10:125-34. 2013
    ..Results of the TOPCAT study of spironolactone in patients with HFpEF are awaited, and LCZ696 is now being tested in a large trial in patients with HFrEF...
  20. ncbi Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines
    Michael McGillion
    University of Toronto, Toronto, Ontario, Canada
    Can J Cardiol 28:S20-41. 2012
    ..Concluding summary recommendations are also made, giving direction to future clinical practice and research on RFA management in Canada...
  21. ncbi The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population
    R Ferrari
    Royal Brompton Hospital, London, UK
    Cardiology 110:271-82. 2008
    ..This report describes the study population at baseline...
  22. ncbi Prostacyclin among prostanoids
    Ryszard J Gryglewski
    Jagiellonian Medical Research Centre, Krakow, Sławkowska 17, PL 31 016 Kraków, Poland
    Pharmacol Rep 60:3-11. 2008
    ..In this way, the foundations for the Endothelial Pharmacology were laid...
  23. ncbi Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management
    Colin Berry
    Department of Medicine, Montreal Heart Institute and Universite de Montreal, Montreal, Quebec, Canada
    J Am Coll Cardiol 49:631-42. 2007
    ..Noncompliance, particularly with lifestyle measures, and underprescription of evidence-based therapies remain important unsolved problems...
  24. ncbi Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin
    Tommaso Angelone
    Department of Cell Biology, Laboratory of Cardiovascular Pathophysiology, University of Calabria, Arcavacata di Rende CS, Italy
    Am J Physiol Heart Circ Physiol 302:H431-42. 2012
    ..Our results are of importance in relation to the putative application of CST as a cardioprotective agent against stress, including excessive sympathochromaffin overactivation...
  25. ncbi Late restenosis following sirolimus-eluting stent implantation
    Nehiro Kuriyama
    Department of Cardiology, Miyazaki Medical Association Hospital, Miyazaki, Japan
    JACC Cardiovasc Interv 4:123-8. 2011
    ..This serial angiographic study evaluated the incidence and predictors of late restenosis after sirolimus-eluting stent (SES) implantation...
  26. ncbi Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine
    Emmanuel Canet
    Institut de Recherches Internationales Servier, Courbevoie, France
    Ann N Y Acad Sci 1222:90-9. 2011
    ..The development of ivabradine represents a clear innovation in the management of cardiovascular disease...
  27. ncbi Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Cardiovasc Ther 26:50-8. 2008
    ..Therefore, in this article, we review several agents with inhibitory effects on AGEs formation and their therapeutic implications in CVD in diabetes...
  28. ncbi 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to devel
    Theodore D Fraker
    Circulation 116:2762-72. 2007
  29. ncbi ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    J Am Coll Cardiol 50:e1-e157. 2007
  30. ncbi A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of th
    Pieter R Stella
    Department of Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Room E 01 207, 3584 CX, Utrecht, The Netherlands
    Catheter Cardiovasc Interv 80:1138-46. 2012
    ..We compared angiographic and clinical outcomes of a provisional T-stenting technique with a DEB plus bare-metal stent (BMS) versus BMS versus paclitaxel DES...
  31. ncbi Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions
    Juan A Herrador
    Unidad de Hemodinamica, Servicio de Cardiologia, Complejo Hospitalario de Jaen, Spain
    Catheter Cardiovasc Interv 78:1086-92. 2011
    ..To compare zotarolimus-eluting stent (Endeavor Sprint®; ZES-S) and the everolimus-eluting stent (Xience V®; EES) in the treatment of coronary bifurcation lesions...
  32. ncbi Patient and general practitioner attitudes to healthy lifestyle behaviours and medication following coronary heart disease: an exploratory study
    Catherine Speechly
    Projects, Research and Development Unit, RACGP NSW and ACT Faculty, 12 Mount Street, North Sydney, NSW 2060, Australia
    Aust J Prim Health 16:154-8. 2010
    ....
  33. ncbi Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial
    Christopher D Gardner
    Stanford Prevention Research Center and the Department of Medicine, Stanford University Medical School, Stanford, California, USA
    Blood Coagul Fibrinolysis 18:787-93. 2007
    ..No adverse bleeding events were observed, although the trial was limited to a small sample size...
  34. ncbi Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization
    Maarten L Simoons
    Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Heart J 31:530-41. 2010
    ..Accordingly, CABG and PCI should be considered a valuable adjunct rather than an alternative to medical therapy...
  35. ncbi Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction
    Angelo A Izzo
    Department of Experimental Pharmacology, University of Naples Federico II, via D Montesano 49, 80131 Naples, Italy
    Int J Cardiol 98:1-14. 2005
    ..John's wort. Interaction between herbal medicine and cardiovascular drugs is a potentially important safety issue. Patients taking anticoagulants are at the highest risk...
  36. ncbi Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first
    Juan Luis Gutiérrez-Chico
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    EuroIntervention 7:711-22. 2011
    ..To test the efficacy of sequential application of drug-coated balloon (DCB) and bare metal stent (BMS) for treatment of de novo coronary lesions, comparing the sequence of application (DCB first vs. BMS first)...
  37. ncbi Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic End
    Martin B Leon
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:1208-18. 2009
    ..The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES) in patients with native coronary lesions...
  38. ncbi Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries
    Aniko Posa
    Department of Cardiology, Medical University of Vienna, Austria
    Catheter Cardiovasc Interv 76:395-403. 2010
    ....
  39. ncbi Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials
    Shuzou Tanimoto
    Department of Interventional Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 70:515-23. 2007
    ..This study sought to evaluate and compare in vivo acute stent recoil of a novel bioabsorbable stent and a metallic stent...
  40. ncbi Drug-eluting stent fracture: incidence, contributing factors, and clinical implications
    Timothy Canan
    Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA
    Catheter Cardiovasc Interv 75:237-45. 2010
    ..Other complications observed with stent fracture include stent thrombosis, coronary aneurysms, myocardial infarction, and sudden death...
  41. ncbi Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction
    Gerd Heusch
    Institut fur Pathophysiologie, Universitatsklinikum Essen, Essen, Germany
    Eur Heart J 29:2265-75. 2008
    ..Heart rate reduction by beta-blockade is associated with negative inotropism and unmasked alpha-adrenergic coronary vasoconstriction. Ivabradine is the only available bradycardic agent for clinical use...
  42. ncbi Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study
    Bernardo Cortese
    Interventional Cardiology Unit, Cardiovascular Department, Ospedale della Misericordia, Grosseto, Italy
    Heart 96:1291-6. 2010
    ..The impact of a PCB during PCI of small coronary vessels was evaluated and compared to one of the most widely used DES...
  43. ncbi Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis
    Demosthenes G Katritsis
    Department of Cardiology, Athens Euroclinic, Athens, Greece
    Circulation 111:2906-12. 2005
    ..Therefore, we performed a meta-analysis of 11 randomized trials comparing PCI to conservative treatment in patients with stable CAD...
  44. ncbi Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
    Bruce L Wilkoff
    The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F 15, Cleveland, OH 44195, USA
    JAMA 288:3115-23. 2002
    ..Most currently implanted ICD devices provide dual-chamber pacing therapy. The most common comorbid cause for mortality in this population is congestive heart failure...
  45. ncbi Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment
    Leong Lee
    Department of Cardiology, University of Nottingham, Queens Medical Centre, Nottingham, England
    Circulation 112:3280-8. 2005
    ..Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients...
  46. ncbi In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial
    Takayuki Okamura
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    EuroIntervention 5:932-8. 2010
    ..1) were introduced for the ABSORB Cohort B study in order to decrease recoil. The aim was to compare in vivo the strut distribution between the BVS revision 1.0 (Cohort A), and BVS revision 1.1 (Cohort B) designs...
  47. ncbi Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries
    Sandeep P Kishore
    Weill Cornell Rockefeller Sloan Kettering Tri Institutional MD PhD Program, New York, New York, USA
    J Am Coll Cardiol 57:1980-7. 2011
    ..Here, we use cardiovascular disease as a specific case study to examine the issue, outlining early solutions while drawing parallels and analogies to the HIV experience...
  48. pmc Medication adherence: a call for action
    Hayden B Bosworth
    Center for Health Services Research in Primary Care, Durham VAMC, Durham, NC, USA
    Am Heart J 162:412-24. 2011
    ..We then summarize proven effective approaches and conclude with a discussion of recommendations to address this growing and significant public health issue of medication nonadherence...
  49. ncbi Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 48:253-61. 2006
    ....
  50. ncbi The challenge of polypharmacy in cardiovascular medicine
    Massimo Volpe
    Cardiology Department, IInd School of Medicine, University of Rome Sapienza, S Andrea Hospital, Rome, Italy
    Fundam Clin Pharmacol 24:9-17. 2010
    ..However, large randomized trials are required to define its impact on clinical outcomes. This review will focus on challenges of polypharmacy in CV medicine, illustrating potential options to face this emerging crisis...
  51. ncbi Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease
    J Virtamo
    National Public Health Institute, Helsinki, Finland
    Arch Intern Med 158:668-75. 1998
    ..Oxidized low-density lipoprotein is involved in the pathogenesis of atherosclerosis. In epidemiological studies antioxidants have been inversely related with coronary heart disease. Findings from controlled trials are inconclusive...
  52. ncbi Treatment of patent ductus arteriosus
    Jonathan Wyllie
    The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK
    Semin Neonatol 8:425-32. 2003
    ..PDA closure can then be achieved using medical means, with surgery reserved for patients in whom this fails or in whom there are contra-indications. However, the optimum timing for intervention remains unknown...
  53. ncbi Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, St Louis University School of Medicine, St Louis, MO, USA
    JAMA 291:309-16. 2004
    ....
  54. ncbi Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches
    Kelly L Miller
    Division of General Internal Medicine, Durham, NC, USA
    Am Heart J 147:401-11. 2004
    ....
  55. ncbi Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor
    Jeffrey S Borer
    Cardiovascular Pathophysiology Unit and The Howard Gilman Institute for Valvular Heart Diseases, Weill Cornell Medical College, New York, NY 10128 1152, USA
    Am J Ther 15:461-73. 2008
    ..They also suggest that management of treatment should be relatively simple in most patients...
  56. ncbi A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study
    Charles Chan
    Department of Cardiology, National Heart Center, Singapore
    Catheter Cardiovasc Interv 72:591-600. 2008
    ..To compare the effects of sirolimus-eluting (SES) versus bare metal stents (BMS) on 6-month in-stent late luminal loss (LLL) and 1-year major adverse cardiac events (MACE) in diabetics undergoing percutaneous coronary interventions...
  57. ncbi Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey
    Dusko Vulic
    Department of Internal Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
    Am J Cardiovasc Drugs 10:109-14. 2010
    ..Most data derive from registries of hospitalized patients or are from clinical trials. Little data exist on goal attainment and adherence with therapy among CHD survivors of major US ethnic groups in the real-world setting...
  58. ncbi Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents
    I Chang Hsieh
    Second Section of Cardiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Coron Artery Dis 24:224-30. 2013
    ..The aim of this study is to evaluate the acute and long-term outcomes of ostial stentings among bare-metal stents (BMS), sirolimus-eluting stents, and paclitaxel-eluting stents...
  59. pmc Medication adherence, self-care behaviour and knowledge on heart failure in urban South Africa: the Heart of Soweto study
    V Ruf
    Soweto Cardiovascular Research Unit, Department of Cardiology, Chris Hani Baragwanath Hospital, Soweto, Johannesburg, South Africa
    Cardiovasc J Afr 21:86-92. 2010
    ..There is a paucity of data on treatment adherence in patients with chronic heart failure (CHF) in Africa...
  60. ncbi Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction
    Robert R West
    Department of Epidemiology, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Heart 98:637-44. 2012
    ..Clinical management has been transformed in the past 30-40 years and the findings of historical trials may have little relevance now...
  61. ncbi Postconditioning the human heart with adenosine in heart valve replacement surgery
    Zhen Xiao Jin
    Institute of Cardiovascular Surgery, Xijing Hospital, Xi an, China
    Ann Thorac Surg 83:2066-72. 2007
    ....
  62. ncbi Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model
    Boris Radeleff
    Department of Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    J Vasc Interv Radiol 21:1262-70. 2010
    ..Toxicity might result from overdosage and/or accumulation. Part 1 of this two-step study investigated how paclitaxel uptake depends on dose density, coronary drug transfer kinetics, and elution efficacy...
  63. ncbi Studies on the antimicrobial potential of the cardiovascular drug lacidipine
    Asish Dasgupta
    Department of Pharmaceutical Technology, Jadavpur University, Calcutta 700 032, India
    In Vivo 21:847-50. 2007
    ..typhimurium NCTC 74. According to the chi-square test, the in vivo data were highly significant (p<0.001)...
  64. ncbi Effectiveness of guideline-recommended cardiac drugs for reducing mortality in the elderly medicare heart failure population: a retrospective, survey-weighted, cohort analysis
    Diane M Richardson
    Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA
    Drugs Aging 27:845-54. 2010
    ..However, the results of randomized controlled trials may not be generalizable to the population most likely (i.e. the elderly) to receive these drugs in clinical practice...
  65. ncbi Paclitaxel-eluting balloon: from bench to bed
    Axel de Labriolle
    Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC, USA
    Catheter Cardiovasc Interv 73:643-52. 2009
    ..We aimed to review the concept, preclinical-, and clinical data available with non-stent based local drug delivery and, in particular, with paclitaxel-eluting balloons...
  66. ncbi Three-year outcome of sirolimus-eluting stent implantation in coronary bifurcation lesions: the provisional side branch stenting approach versus the elective two-stent approach
    Toshihiro Tamura
    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    EuroIntervention 7:588-96. 2011
    ..To explore optimal management strategies for bifurcation lesions with sirolimus-eluting stents (SES)...
  67. ncbi A retrospective, observational cohort analysis of a nationwide database to compare heart failure prescriptions and related health care utilization before and after publication of updated treatment guidelines in the United States
    Shirin Shafazand
    Division of Pulmonary and Critical Care Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Clin Ther 32:1642-50. 2010
    ....
  68. ncbi Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study
    Claudius Jacobshagen
    Department of Cardiology and Pneumology, Georg August University, Robert Koch Strasse 40, Gottingen, Germany
    Clin Cardiol 34:426-32. 2011
    ..So far, there has been no specific treatment for impaired left ventricular (LV) relaxation. Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current...
  69. ncbi Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach
    Francesco Burzotta
    Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
    JACC Cardiovasc Interv 4:327-35. 2011
    ..This study sought to compare the procedural performance and the acute angiographic result on side-branch ostium obtained using 2 different drug-eluting stents (DES) to treat patients with bifurcated coronary lesions...
  70. ncbi Flavanol-rich cocoa ameliorates lipemia-induced endothelial dysfunction
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, Leipziger Str 44, 39120 Magdeburg, Germany
    Heart Vessels 26:511-5. 2011
    ..Flavanols did not have any influence on triglycerides or on free fatty acids. Flavanol-rich cocoa can alleviate the lipemia-induced endothelial dysfunction, probably through an improvement in endothelial NO synthase...
  71. ncbi Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial
    Alexandra J Lansky
    Yale University School of Medicine, New Haven, CT 06520, USA
    EuroIntervention 6:J44-52. 2010
    ..Side branch occlusion was defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or 1. Clinical outcomes through three years were compared by stent type and presence of side branch occlusion...
  72. ncbi Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report
    Dobrin Vassilev
    Cardiac Catheterization Laboratory, National Heart Hospital, Sofia, Bulgaria
    Catheter Cardiovasc Interv 80:1223-6. 2012
    ..The patient was left on double antiplatelet therapy and scheduled for clinical observation after 3 months and control coronary angiography after 6 months for aneurysm progression follow-up...
  73. ncbi Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)
    H Shigematsu
    Department of Vascular Surgery, Tokyo Medical University, Shinjuku ku, Tokyo, Japan
    Int Angiol 29:2-13. 2010
    ..To investigate the current status of peripheral arterial disease (PAD) drug treatment in Japan, and the effects of drug treatment, risk factors, and complications on disease progress and onset of cardiovascular events in PAD patients...
  74. ncbi Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride
    Kaushiki Mazumdar
    Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Calcutta 700 032, India
    Microbiol Res 158:259-64. 2003
    ..The in vivo results were highly significant according to chi-square test...
  75. ncbi Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation
    Christian Herdeg
    Medizinische Klinik III, Eberhard Karls Universitat Tubingen, Germany
    Circ Cardiovasc Interv 2:294-301. 2009
    ..We assessed the safety and efficacy of catheter-based local delivery of fluid paclitaxel in patients with coronary de novo stenoses after implantation of a bare metal stent...
  76. ncbi Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry
    Ian Meredith
    MonashHeart, Monash Medical Centre and University, Melbourne, Australia
    Catheter Cardiovasc Interv 77:993-1000. 2011
    ..To present data from the cohort of patients in the all-comers Endeavor zotarolimus-eluting stent (ZES) registry (E-Five) who underwent 2-year follow-up...
  77. ncbi A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial
    Raul Moreno
    University Hospital La Paz, Madrid, Spain
    EuroIntervention 6:112-6. 2010
    ..The primary endpoint will be angiographic in-stent late loss...
  78. ncbi Coronary pseudoaneurysm in a non-polymer drug-eluting stent: a rare entity
    Aditya Kapoor
    Department of Cardiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
    Asian Cardiovasc Thorac Ann 19:407-10. 2011
    ..We describe a case of coronary pseudoaneurysm developing with a non-polymer-based drug-eluting stent in a 50-year-old man who was successfully managed by coronary artery bypass grafting...
  79. ncbi Gender differences in evidence-based pharmacological therapy for patients with stable coronary heart disease
    Carlos Lahoz
    Hospital Carlos III, Madrid, Spain
    Int J Cardiol 133:336-40. 2009
    ..We analyzed the prescription rates of evidence-based pharmacological therapies for patients with stable coronary heart disease and whether there were any differences with respect to gender...
  80. ncbi Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus
    Rosli Mohd Ali
    National Heart Institute, Kuala Lumpur, Malaysia
    EuroIntervention 7:K83-92. 2011
    ..Encouraging clinical data of the drug-eluting balloon catheter (DEB) SeQuent Please warrant its investigation in these patients...
  81. ncbi Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease
    Claudio Allegra
    San Giovanni Hospital, Rome, Italy
    Ann Vasc Surg 22:552-8. 2008
    ..From these preliminary data has emerged an indication of therapy with PLC for chronic obstructive arteriopathy of the lower limbs at stage II. Further studies with higher numbers of patients and more controlled variables are planned...
  82. ncbi Ranolazine: a review of its use in chronic stable angina pectoris
    M Asif A Siddiqui
    Adis International Limited, Auckland, New Zealand
    Drugs 66:693-710. 2006
    ..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional haemodynamic antianginal therapy in the treatment of chronic stable angina...
  83. ncbi Systems biology approaches to the study of cardiovascular drugs
    Yuri Nikolsky
    GeneGo, Inc, St Joseph, MI, USA
    Methods Mol Biol 662:221-43. 2010
    ..All relevant steps, for example, experimental design, tissue collection and high quality RNA preparation, bioinformatical analysis of functional processes, and pathways (targeted and untargeted) are addressed...
  84. ncbi Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study
    Chiara Melloni
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 6:9-16. 2008
    ....
  85. ncbi Pharmacological activity of cardiovascular agents from herbal medicine
    John W Ho
    Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
    Cardiovasc Hematol Agents Med Chem 5:273-7. 2007
    ..The study will provide insights into drug action and demonstrate the therapeutic benefits of herbal medicine for the treatment of cardiovascular disease...
  86. ncbi Methods for identifying cardiovascular agents: a review
    David Anthony Tulis
    Cardiovascular Disease Research Program, J L Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA
    Recent Pat Cardiovasc Drug Discov 1:47-56. 2006
    ..The invention disclosed in Methods for identifying cardiovascular agents [1] provides screening methods which can be used to identify certain suspected cardiovascular agents that ..
  87. ncbi Telmisartan prevents cardiovascular events in a broad group of at-risk patients
    Magnus Baumhakel
    University Hospital of the Saarland, Department of Cardiology, Homburg Saar, Germany
    Expert Opin Pharmacother 10:3113-7. 2009
    ..In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial...
  88. ncbi Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study
    Stefan Störk
    Department of Internal Medicine I Center for Cardiovascular Medicine, University of Wurzburg, Klinikstrasse 6 8, D 97070 Wurzburg, Germany
    Eur J Heart Fail 10:1236-45. 2008
    ..The effectiveness of chronic heart failure (CHF) pharmacotherapy in unselected cohorts is unknown...
  89. ncbi Ranolazine (Ranexa) in the treatment of chronic stable angina
    Sajid Aslam
    Division of Cardiovascular Medicine, University Hospital, Nottingham, UK
    Adv Ther 27:193-201. 2010
    ..This review provides an insight into this treatment option, describes the clinical trials evidence, proposed mechanism of action, and pharmacokinetics, and outlines the indications for its use in chronic stable angina...
  90. ncbi Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography
    Rory Hachamovitch
    Department of Imaging, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, Calif 90048, USA
    Circulation 107:2900-7. 2003
    ....
  91. ncbi Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1199-207. 2009
    ....
  92. ncbi Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution
    A R Sielecki
    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Science 243:1346-51. 1989
    ..Knowledge of the actual structure, as opposed to the use of models based on related enzymes, should facilitate the design of renin inhibitors...
  93. pmc Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
    Giorgia De Berardis
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
    BMJ 339:b4531. 2009
    ..To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease...
  94. ncbi Vasoprotection by nitric oxide: mechanisms and therapeutic potential
    Michael T Gewaltig
    Institut fur Pharmakologie und Klinische Pharmakologie, Medizinische Einrichtungen, Heinrich Heine Universitat, Moorenstrasse 5, 40225, Dusseldorf, Germany
    Cardiovasc Res 55:250-60. 2002
    ..Finally, L-arginine or new activators of the NO pathway may become therapeutic options in the future...
  95. ncbi The implications of therapeutic complexity on adherence to cardiovascular medications
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    Arch Intern Med 171:814-22. 2011
    ..Our objective was to estimate the extent of prescribing and filling complexity in patients prescribed a cardiovascular medication and to evaluate its association with adherence...
  96. ncbi Loss of cardioprotection with ageing
    Kerstin Boengler
    Institut fur Pathophysiologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cardiovasc Res 83:247-61. 2009
    ..g. ischaemic pre and postconditioning in aged organs and animals will be discussed, and the development of strategies aimed to antagonize the age-induced loss of protection will be addressed...
  97. pmc Regulation and pharmacology of the mitochondrial permeability transition pore
    Dmitry B Zorov
    Laboratory of Cardiovascular Science, Gerontology Research Center, Box 13, Intramural Research Program, National Institute on Aging, NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224 6825, USA
    Cardiovasc Res 83:213-25. 2009
    ..This review provides an update on the current state of knowledge regarding the regulation of the mPTP...
  98. ncbi Reproducibility of quantitative optical coherence tomography for stent analysis
    Nieves Gonzalo
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    EuroIntervention 5:224-32. 2009
    ..To assess the inter- and intra- observer reproducibility for strut count, strut apposition and strut tissue coverage measurements with optical coherence tomography (OCT)...
  99. ncbi Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial
    Ian T Meredith
    Monash Heart Monash Medical Centre and University, Melbourne, Australia
    JACC Cardiovasc Interv 2:977-85. 2009
    ..The RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California)...
  100. ncbi Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial
    Keiichi Tsuchida
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 67:188-97. 2006
    ..05). Our proposed QCA volumetric measurements may be a practical surrogate for IVUS measurements and a discriminant methodological approach for assessment of treatment effects of drug-eluting stents...
  101. ncbi Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial
    Marie Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    JAMA 295:895-904. 2006
    ....

Research Grants63

  1. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2010
    ..believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
  2. Azithromycin and Sudden Cardiac Death: Electrophysiologic Mechanisms
    Katherine T Murray; Fiscal Year: 2013
    ..Thus, an improved understanding of the basic mechanisms causing azithromycin-induced sudden cardiac death should lead to safer pharmacotherapy. ..
  3. Metabolomics Network for Drug Response Phenotype
    RIMA F KADDURAH DAOUK; Fiscal Year: 2010
    ..Such knowledge can lead to more effective and personalized therapies. ..
  4. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  5. Dual-frequency intravascular arrays for functional imaging of atherosclerosis
    XIAONING JIANG; Fiscal Year: 2013
    ....
  6. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  7. Heterocyclic Analogues of Podophyllotoxin Accessible by a One-Step Multicomponent
    Alexander Kornienko; Fiscal Year: 2009
    ..It involves the utilization of a naturally occurring plant metabolite, podophyllotoxin, for the design, preparation and testing of synthetic molecules expected to be toxic to cancer cells. ..
  8. ETIOLOGY OF BLOOD DYSCRASIAS--ANALYSIS OF THE IAAAS DATA
    David Kaufman; Fiscal Year: 1990
    ..The proposed grant will enable the full scientific and public health benefits to be obtained from this unique resource, st a modest incremental cost...
  9. Atrial natriuretic peptide receptor crystallization
    Focco van den Akker; Fiscal Year: 2004
    ..Our long term structural studies on the molecular mechanism of ANP receptor signaling could enhance the development of renal and cardiovascular drugs. ..
  10. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2006
    ..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
  11. SEX STEROID HORMONES--EFFECTS ON DRUG CLEARANCE IN MAN
    Thomas Walle; Fiscal Year: 1991
    ..More generally, these studies will establish a solid base, in man as well as in animal and cell model systems, from which mechanistic studies on the influence of sex steroid hormones on drug clearance in man can be undertaken...
  12. SINGLE-CHAIN FV-PEPTIDE FUSION INHIBITOR OF FIBRIN CLOTS
    Mei Sheng Tai; Fiscal Year: 1991
    ..The data from these studies will permit a clear formulation of a Phase II project that can take full advantage of our expertise in the engineering of sFv fusion proteins...
  13. NEW MARINE SOURCES OF CARDIOVASCULAR AGENTS
    FREDERICK FUHRMAN; Fiscal Year: 1980
    ..Perfused rabbit ears would be used for study of vasodilator activity. We would attempt to determine chemical structure principally from mass and nmr spectral studies...
  14. AUTOMATED HOME TABLET AND CAPSULE DISPENSER
    Thomas Shaw; Fiscal Year: 1990
    ..It also provides complete logging, is secure against theft and fully portable allowing for "pass medication."..
  15. AUTOMATED HOME TABLET AND CAPSULE DISPENSER
    Thomas Shaw; Fiscal Year: 1993
    ..It also provides complete logging, is secured against theft, and is fully portable, allowing for patient use during overnight or weekend visit...
  16. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2005
    ..We have continued to examine the imoortance of this mutation to the vascular response. ..
  17. MODELS FOR BIOLOGICAL DATA RELEVANT TO HEALTH CARE
    Davide Verotta; Fiscal Year: 1999
    ....
  18. THYROID HORMONE AND CELLULAR CALCIUM REGULATION
    Laura Kragie; Fiscal Year: 1992
    ..dihydropyridine efficacy in (1) ameliorating symptoms associated with thyroid disorders and (2) as cardiovascular agents in patients with concombinant cardiovascular and thyroid disease...
  19. EFFECT OF SYSTEMIC DRUGS ON TEAR PRODUCTION
    MICHAEL LEMP; Fiscal Year: 1980
    ..taken by millions of patients with diverse disease (antihistamines, antispasmodics, anti-Parkinson drugs, cardiovascular agents, psychotropic drugs) have anticholinergic effects and seem to have an adverse effect on tear production...
  20. MD & PATIENT ACCEPTANCE OF MICROPROCESSOR DRUG DISPENSER
    ESTHER KLAY; Fiscal Year: 1990
    ..e., cardiovascular drugs, asthmatics, antidepressants, etc.). Additional applications could include monitoring, accounting for and controlling narcotics in the hospital and use in clinical trials for investigational agents...
  21. Inhibitors of PAR1-G13 Interface for Arthersclerosis
    Annette Gilchrist; Fiscal Year: 2002
    ..Hundreds of billions of dollars are spent each year treating heart disease. In 1998, it was estimated that sales of cardiovascular drugs alone were $37 billion. ..
  22. BETA-ADRENERGIC RECEPTOR POLYMORPHISMS AND HYPERTENSION
    Julie Johnson; Fiscal Year: 2003
    ..the BAR genotype significantly impacts the BP response to B-blockers could lead to improved patient outcomes, as patients could be genotyped prior to institution of B-blocker therapy, thus avoiding this therapy in those likely to respond ..
  23. Primary Cardiomyopathies in Children: Research Directions & Strategies
    Steven Lipshultz; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  24. Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
    Steven Lipshultz; Fiscal Year: 2009
    ..If the HFE mutations are related to increased cardiotoxicity of anthracyclines. This study will elucidate the molecular mechanisms of anthracycline cardiotoxicity in pediatric ALL cancer survivors. ..
  25. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2009
    ..These studies will dramatically increase our understanding of pediatric cardiomyopathy, suggest new areas of research and improved patient management. ..
  26. HAART Associated Cardiotoxicity in HIV-Infected Children
    Steven Lipshultz; Fiscal Year: 2008
    ..The findings will help determine the need for cardiovascular follow-up, prevention and therapeutic trials. ..
  27. Cardiovascular Status of HAART-Exposed Infants/Children
    Steven Lipshultz; Fiscal Year: 2006
    ..This study will determine the cardiovascular effects of HAART in seroreverters and the need for future cardiovascular follow-up and cardiovascular preventive and therapeutic trials in this rapidly expanding population. ..
  28. CARDIAC RISK FACTORS IN PEDIATRIC CANCER SURVIVORS
    Steven Lipshultz; Fiscal Year: 2002
    ..If the hypotheses are true, this should enable more rational recommendations for preventive cardiology in long-term survivors to be made and to standardize care and management for this population. ..
  29. Beta-adrenoceptor genetic polymorphisms and obesity
    Julie Johnson; Fiscal Year: 2002
    ..Additionally, genotyping individuals early in age may help to identify those at increased risk of obesity prior to them becoming obese so that they may take appropriate preventive measures. ..
  30. Beta-receptors and cardiovascular pharmacogenomics
    Julie Johnson; Fiscal Year: 2006
    ..abstract_text> ..
  31. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
    ..The proposed studies should add substantial new information about antihypertensive pharmacogenetics, and could influence how antihypertensive medications are prescribed in the future. ..
  32. HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
    Dan Roden; Fiscal Year: 2006
    ..Moreover, variability in the extent of rifampin-mediated induction of the drug metabolizing enzyme, CYP3A, among subjects with variant OATP-C alleles, will also be tested. [unreadable] [unreadable]..
  33. Automated Storage and Retrieval of Biological Systems
    Dan Roden; Fiscal Year: 2008
    ..Accordingly, this proposal requests a high end instrument to accomplish these goals, and to thereby enable a new era of Personalized Medicine. [unreadable] [unreadable] [unreadable] [unreadable]..
  34. Molecular Pathology of Cardic Arrhythmias
    Dan Roden; Fiscal Year: 2003
    ..abstract_text> ..
  35. Prescription Drug Coverage and Health Outcomes in Elders
    Jennifer Tjia; Fiscal Year: 2008
    ..abstract_text> ..
  36. Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
    Lori J Mosca; Fiscal Year: 2010
    ..Improved adherence to evidence-based preventive therapies could have a substantial public health benefit. ..
  37. Transforming PCI Informed Consent into an Evidence-based Decision-making Tool
    John A Spertus; Fiscal Year: 2010
    ..We will then estimate the cost-savings associated with more rational BAT use to test the hypothesis that PRISM will improve the cost-effectiveness of PCI. ..
  38. Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD)
    Sunil Kripalani; Fiscal Year: 2009
    ..Program costs will also be assessed. If successful, this intervention could offer an important means of reducing medication errors in the post-hospitalization period. ..
  39. Role of Progenitor Cells in Cardiovascular Medicine
    Douglas W Losordo; Fiscal Year: 2010
    ..Accordingly, in this proposal we will employ a series of in vivo and in vitro model systems to define the role of EPCs in recovery from myocardial ischemia with a goal of developing future therapeutic strategies exploiting these cells. ..
  40. Effect of Drugs on Myocardial Hypoxia
    Garrett Gross; Fiscal Year: 2009
    ..Information gained from these studies will hopefully lead to new therapies to treat patients with ischemic heart disease. ..
  41. Vessel Remodeling During Ductus Arteriosus Closure
    Ronald I Clyman; Fiscal Year: 2010
    ..These studies should increase our understanding of the mechanisms that prevent the preterm DA from closing and remodeling after birth. ..
  42. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  43. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  44. Progenitor Cells in Vascular Biology
    Douglas Losordo; Fiscal Year: 2008
    ..The ultimate goal of these studies is to identify future clinical strategies for tissue repair. ..
  45. ESTROGEN, ANGIOGENESIS AND ENDOTHELIAL PROGENITOR CELLS
    Douglas Losordo; Fiscal Year: 2004
    ..abstract_text> ..
  46. Domoic Acid and Neonatal Microglia Activation
    Alejandro Mayer; Fiscal Year: 2004
    ..activated microglia cells and their mediators play in DOM-induced excitotoxic neuronal injury and thus contribute to potential novel approaches for the therapy of the neuropathology associated with Amnesic Shellfish Poisoning in humans ..
  47. Comparing Effects of 3 Sources of Garlic on Serum Lipids
    Christopher Gardner; Fiscal Year: 2005
    ..The comprehensive approach taken in this study will provide important evidence for both the public and for health professionals as to whether fresh garlic or garlic supplements have beneficial effects on serum lipids. ..
  48. Genetic Predictors of Outcome in Acute MI
    Marc Sabatine; Fiscal Year: 2005
    ..Genomic control will be employed to detect and control for population stratification. Interaction terms will be incorporated into regression models to explore gene-environment and pharmacogenomic interactions. ..
  49. ACTION-A CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISE
    William Abraham; Fiscal Year: 2005
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  50. RESTENOSIS AND ENDOTHELIAL PROLIFERATION
    Douglas Losordo; Fiscal Year: 2007
    ..Together these studies will result in a better understanding of the mechanisms, which govern EC recovery at sites of balloon injury and may lead to novel therapeutic strategies targeting endothelial recovery. [unreadable] [unreadable]..
  51. Effect of Antioxidants on Inflammatory Markers and FMVD
    Christopher Gardner; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  52. Training in Medication Compliance and Health Literacy
    Sunil Kripalani; Fiscal Year: 2008
    ..If successful, the proposed research could serve as a model for other interventions to improve compliance and cardiovascular care, particularly among low-literate and underserved populations. ..
  53. Utility of a New Database to Study Drug Safety during Pregnancy
    SOKO SETOGUCHI IWATA; Fiscal Year: 2008
    ..This database based on large population-based follow-up data with linkable clinical birth data has the potential to enhance the safety of prescription drug use in pregnant women and their children. [unreadable] [unreadable] [unreadable]..
  54. REDUCTION OF TRIGLYCERIDES IN WOMEN ON HRT
    Lewis Kuller; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  55. PRICE: Pivotal Research in Cardiology in the Elderly
    Michael Rich; Fiscal Year: 2008
    ....
  56. ALA & EPA/DHA (w-3) Effects On Inflammatory Markers in Insulin Resistant Adults
    Christopher Gardner; Fiscal Year: 2007
    ..The adults with the metabolic syndrome selected for this study are those that are at increased risk of heart disease, and those most likely to be benefit from the different therapies tested. [unreadable] [unreadable] [unreadable]..
  57. Plasminogen activators and cerebral ischemic injury
    William M Armstead; Fiscal Year: 2010
    ....
  58. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2005
    ..These studies may lead to therapies for brain injured children. ..
  59. Comprehensive Laboratory Animal Monitoring System
    Martin Young; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..